Skip to content

All recalls FDA

FDADrugsRecalled Status: Ongoing

Breckenridge Pharmaceutical, Inc. recalls Duloxetine Delayed-Release Capsules

Class IIofficial

FDA Class II

FDA classified this recall as Class II: the product may cause health problems that are temporary or can be treated; the chance of serious harm is remote.

Hazard
CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit
Products
  • Duloxetine Delayed-Release Capsules
Where it was sold

Nationwide within the United States

Nationwide

Units affected
359,676 bottles
About this recall
Duloxetine Delayed-Release Capsules, USP, 60mg, packaged in a) 90 Capsules (NDC 51991-748-90); b) 1000 Capsules (51991-748-10), Rx Only, Mfr. by: Towa Pharmaceutical Europe, S.L. Martorelles, (Barcelona), Spain, Dist. by: Breckenridge Pharmaceuticals, Inc., Berkeley Heights, NJ 07922.